scholarly journals A novel adipose hormone asprosin as a potential breast cancer marker

2021 ◽  
Author(s):  
Sibel OZCAN ◽  
Nilgun YILDIRIM ◽  
Mesut YUR ◽  
Mehmet Ridvan OZDEDE ◽  
Mete OZCAN
Keyword(s):  
Breast Cancer ◽  
Odds Ratio ◽  
Roc Analysis ◽  
Gynecological Cancer ◽  
Multivariable Analysis ◽  
Serum Levels ◽  
Regression Analyses ◽  
Obese Adults ◽  
Potential Association ◽  
History Of

Abstract PurposeAsprosin is a recently discovered hormone released by white adipose tissue (WAT) that is typically significantly elevated in obese adults. Consequently, the adverse effects of increasing WAT in obesity during breast cancer (BC) development and progression have attracted interest of researchers and clinical practitioners. Thus, the aim of the present study was to determine whether the asprosin levels are associated with the probability of women having BC. MethodsThe study sample comprised of 45 female patients diagnosed with invasive BC and 42 healthy women that served as controls. Asprosin serum level was quantified in all subjects by ELISA, whereas serum levels of CEA and CA 15–3 were measured using an immunology analyzer. The potential association between asprosin and BC was examined through logistic regression analyses, while samples provided by BC patients were further subjected to ROC analysis to assess the diagnostic accuracy of asprosin. ResultsAsprosin levels were significantly higher in BC patients compared to healthy controls (2.38 ± 0.54 vs. 1.39 ± 0.53 ng/mL, p < 0.001). Multivariable analysis showed that the increased asprosin levels were associated with a significantly higher risk of breast cancer after adjustments for family history of breast and/or gynecological cancer, dyslipidemia, and BMI (odds ratio = 157.92; 95% confidence interval = 17.22−1447.96). When 1.78 ng/mL was adopted as the cut-off value, AUC, sensitivity, and specificity of asprosin for BC were 0.943, 91.1%, and 88.1%, respectively. ConclusionsOur findings demonstrate that asprosin is elevated in BC and can thus be an appropriate candidate for breast cancer diagnosis.

scholarly journals Assessment of Breast Cancer Risk Based on Mammary Gland Volume Measured with CT

2010 ◽  
Vol 4 ◽  
pp. BCBCR.S5248 ◽  
Author(s):  
Megumi Kuchiki ◽  
Takaaki Hosoya ◽  
Akira Fukao
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Patients ◽  
Odds Ratio ◽  
Premenopausal Women ◽  
Breast Cancer Patients ◽  
History Of ◽  
The Relationship

We investigated the relationship between mammary gland volume (MGV) of the breast as measured with three-dimensional chest computed tomography (CT) and breast cancer risk. Univariate analysis was used to assess the relationship between MGV and known risk factors in 427 healthy women. A case control study (97 cases and 194 controls) was conducted to assess breast cancer risk. MGV was significantly smaller for postmenopausal women than for premenopausal women, and was significantly larger for women with a family history of breast cancer than for women without. MGV, body mass index (BMI), and rate of family history of breast cancer were significantly higher among breast cancer patients than among healthy women, and number of deliveries was significantly lower among breast cancer patients. In postmenopausal women, age at menarche was significantly younger for breast cancer patients. MGV correlated well with breast cancer risk factors. The highest odds ratio was 4.9 for premenopausal women with the largest MGV. Regardless of menopausal status, the greater the MGV, the higher the odds ratio. Our results constitute the first reliable data on the relationship between MGV and breast cancer obtained through exact volume analysis.

Gynecological Cancer as a Second Malignancy in Patients With Breast Cancer

2017 ◽  
Vol 27 (6) ◽  
pp. 1298-1304 ◽  
Author(s):  
Budhi Singh Yadav ◽  
Suresh C. Sharma ◽  
Firuza D. Patel ◽  
Bhavana Rai ◽  
Sushmita Ghoshal
Keyword(s):  
Breast Cancer ◽  
Risk Factor ◽  
Relative Risk ◽  
Family History ◽  
Hormonal Therapy ◽  
Gynecological Cancer ◽  
Significant Risk ◽  
Second Primary ◽  
Second Malignancy ◽  
History Of

PurposeThe aim of this study was to determine the incidence and risk factors for gynecological cancer as second malignancy (SM) after treatment of breast cancer (BC).Methods and MaterialsBetween January 1985 and December 2007, a total of 2756 patients with BC were analyzed for gynecological cancers as an SM. Analysis was carried out for patient-, disease-, and treatment-related characteristics. The Cox proportional hazards regression model was used to estimate the relative risk of gynecologic malignancies.ResultsThe median age at BC diagnosis was 49 years and median follow-up of 14 years. In total, 25 cases of gynecological cancer were noted with an incidence of 0.9%. We observed 9 ovarian and endometrium (0.3%) as well as 7 uterine cervix (0.25%) cancers. Family history of BC was the most significant risk factor for SM (relative risk, 7.4; 95% confidence interval, 3.03–18.28; P<0.001). Women with a family history of BC had a higher incidence of endometrial (12%) and ovarian (16%) cancer compared with those who have no family history (0.1%, P = 0.003). Statistically significant higher incidence of endometrial cancer was seen in patients undergoing hormonal therapy (0.4%) as compared with those who are not undergoing hormonal therapy (0.1%, P = 0.001). Most of the endometrial (88.9%) and cervical (71%) cancers were detected at an early stage but ovarian cancers (66.6%) in advanced stage. Chemotherapy and radiotherapy did not increase the risk of gynecological SM.ConclusionsWomen with BC are at risk of developing a second primary gynecological malignancy particularly of endometrium and ovary. Family history of BC was a high risk factor for gynecologic SM. These patients should be followed up for its early detection.

scholarly journals Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems

2016 ◽  
Vol 12 (6) ◽  
pp. e697-e709 ◽  
Author(s):  
Anosheh Afghahi ◽  
Maya Mathur ◽  
Caroline A. Thompson ◽  
Aya Mitani ◽  
Joseph Rigdon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Health Care ◽  
Cancer Registry ◽  
Odds Ratio ◽  
Care Setting ◽  
Health Care Systems ◽  
Multivariable Analysis ◽  
Health Care Setting ◽  
Dual Use ◽  
Care Systems

Purpose: The 21-gene recurrence score (RS) identifies patients with breast cancer who derive little benefit from chemotherapy; it may reduce unwarranted variability in the use of chemotherapy. We tested whether the use of RS seems to guide chemotherapy receipt across different cancer care settings. Methods: We developed a retrospective cohort of patients with breast cancer by using electronic medical record data from Stanford University (hereafter University) and Palo Alto Medical Foundation (hereafter Community) linked with demographic and staging data from the California Cancer Registry and RS results from the testing laboratory (Genomic Health Inc., Redwood City, CA). Multivariable analysis was performed to identify predictors of RS and chemotherapy use. Results: In all, 10,125 patients with breast cancer were diagnosed in the University or Community systems from 2005 to 2011; 2,418 (23.9%) met RS guidelines criteria, of whom 15.6% received RS. RS was less often used for patients with involved lymph nodes, higher tumor grade, and age < 40 or ≥ 65 years. Among RS recipients, chemotherapy receipt was associated with a higher score (intermediate v low: odds ratio, 3.66; 95% CI, 1.94 to 6.91). A total of 293 patients (10.6%) received care in both health care systems (hereafter dual use); although receipt of RS was associated with dual use (v University: odds ratio, 1.73; 95% CI, 1.18 to 2.55), there was no difference in use of chemotherapy after RS by health care setting. Conclusion: Although there was greater use of RS for patients who sought care in more than one health care setting, use of chemotherapy followed RS guidance in University and Community health care systems. These results suggest that precision medicine may help optimize cancer treatment across health care settings.

scholarly journals Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana

2021 ◽  
pp. 965-975
Author(s):  
Hannah Ayettey Anie ◽  
Joel Yarney ◽  
Olutobi Sanuade ◽  
Shivanshu Awasthi ◽  
Tom Akuetteh Ndanu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Nuclear Medicine ◽  
Adjuvant Chemotherapy ◽  
Teaching Hospital ◽  
Odds Ratio ◽  
Multivariable Analysis ◽  
Cox Proportional Hazards Model ◽  
Sub Saharan Africa ◽  
P Value ◽  
Low Middle Income Countries

PURPOSE It is established that addition of systemic therapy to locoregional treatment for breast cancer improves survival. However, reliable data are lacking about the outcomes of such treatment in women with breast cancer in low middle-income countries. We compared the outcomes of treatment in patients who had received neoadjuvant chemotherapy (NACT) or adjuvant chemotherapy and examined the factors associated with breast cancer recurrence and survival at the National Radiotherapy Oncology and Nuclear Medicine Centre, Korle Bu Teaching Hospital, Ghana. METHODS This was a retrospective cohort study. The medical charts of women with breast cancer managed at the National Radiotherapy Oncology and Nuclear Medicine Centre from 2005 to 2014 were reviewed. A total of 388 patients with a median follow-up of 48 months were included in the study. Logistic regression was used to estimate the risk of recurrence. Survival was estimated using cox proportional hazards model. All models were adjusted with clinicopathologic variables. A P value of < .05 was considered statistically significant. RESULTS Fifty-nine percent received adjuvant chemotherapy. In an adjusted logistic model, no difference was observed in locoregional recurrence between patients receiving NACT compared with those receiving adjuvant chemotherapy (odds ratio = 1.05; 95% CI, 0.44 to 2.47). However, NACT recipients had a higher likelihood of distant recurrence (odds ratio = 1.97; 95% CI, 1.24 to 3.15). In a multivariable analysis, no differences were observed in overall survival between the two chemotherapy groups (hazard ratio = 1.43; 95% CI, 0.91 to 2.26). CONCLUSION NACT yields similar outcomes compared with adjuvant chemotherapy; however, recipients of NACT with advanced disease may have more distant failures. Early detection in a resource-limited setting is therefore crucial to optimal outcomes, significantly limiting recurrence and improving survival.

scholarly journals Association of Family History with the Development of Breast Cancer: A Cohort Study of 129,374 Women in KoGES Data

2021 ◽  
Vol 18 (12) ◽  
pp. 6409
Author(s):  
Hyo Geun Choi ◽  
Jung Ho Park ◽  
Yeon Ju Choi ◽  
Yong Joon Suh
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Family History ◽  
Odds Ratio ◽  
Significant Risk ◽  
Premenopausal Women ◽  
Significant Risk Factor ◽  
Large Cohort ◽  
Large Cohort Study ◽  
History Of

Background: Breast cancer is the most common cancer among women. The Korean Genome and Epidemiology Study (KoGES) is a large cohort study that is available to the public. Using this large cohort study, we aimed to unravel the relationship between breast cancer development and a family history of breast cancer in Korea. Methods: This cohort study relied on data from the KoGES from 2001 through 2013. A total of 211,725 participants were screened. Of these, 129,374 women were evaluated. They were divided into two groups, including participants with and without breast cancer. A logistic regression model was used to retrospectively analyze the odds ratio of breast cancer history in families of women with and without breast cancer. Results: Of 129,374 women, 981 had breast cancer. The breast cancer group had more mothers and siblings with histories of breast cancer (p < 0.001). A history of breast cancer in the participant’s mother resulted in an odds ratio of 3.12 (1.75–5.59), and a history of breast cancer in the participant’s sibling resulted in an odds ratio of 2.63 (1.85–3.74). There was no interaction between the history of maternal breast cancer and the history of sibling breast cancer. Based on the subgroup analysis, family history was a stronger factor in premenopausal women than in menopausal and postmenopausal women. Conclusions: A family history of breast cancer is a significant risk factor for breast cancer in Korea. Premenopausal women with a maternal history of breast cancer are of particular concern. Intensive screening and risk-reducing strategies should be considered for this vulnerable subpopulation.

scholarly journals Reduced serum levels of anti-Mullerian hormone is a putative biomarker of early knee osteoarthritis in middle-aged females at menopausal transition

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Eiji Sasaki ◽  
Daisuke Chiba ◽  
Seiya Ota ◽  
Yuka Kimura ◽  
Shizuka Sasaki ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Knee Osteoarthritis ◽  
Odds Ratio ◽  
Area Under Curve ◽  
Roc Analysis ◽  
Serum Levels ◽  
Menopausal Transition ◽  
Middle Aged ◽  
Knee Oa ◽  
Female Hormones

AbstractA recent epidemiological study revealed that the highest prevalence of early knee osteoarthritis (OA) was observed in females aged ≥ 50 years. The major causal factor of early knee OA was sex. Despite the relevance of estrogen in evaluating chondral and bone metabolism in OA, it is not easily clinically monitored because irregular menstrual cycles induce unstable female hormone patterns during menopausal transitions. Anti-Mullerian hormone (AMH) has been found to be a new stable biomarker to predict menopause. This study aimed to investigate the association between menopausal transition and early knee OA by using serum biomarkers, with special focus on AMH. A total of 518 female volunteers who participated in the Iwaki cohort study were enrolled and divided into pre-menopause and post-menopause groups. Weight-bearing anterior–posterior knee radiographs were classified by Kellgren–Lawrence (KL) grade, and grade ≥ 2 was defined as radiographic knee OA. In participants with KL grades 0 and 1, early knee OA was defined by Luyten’s criteria. AMH, luteinizing hormone, follicle-stimulating hormone, estradiol (pg/ml), prolactin, and testosterone were measured on the female hormones. Bone mineral density at a distal radius was measured. The predictive power of female hormones for early knee OA was estimated by ROC analysis (comparison of area under curve, AUC) and regression analysis. Fifty-two participants (10.0%) were diagnosed with early knee OA and 204 (39.4%) with radiographic knee OA. In 393 (75.9%) females, menopause began. From the ROC analysis in pre-menopausal females, cutoff value of AMH for detecting early knee OA was 0.08 ng/ml (area under curve (AUC), 0.712; 95% CI, 0.527–0.897; p value, 0.025; odds ratio, 8.28). AUCs of other female hormones did not reach the level of AMH (range, 0.513 of prolactine to 0.636 of estradiol). Logistic regression analysis focusing on AMH reduction at menopausal transition showed that the related AMH below 0.08 ng/ml was significantly related to the presence of early knee OA (p = 0.035; odds ratio, 5.55). Reduced serum levels of AMH in middle-aged females were correlated with the presence of early knee OA, which might be a useful serum biomarker.

scholarly journals Perfluoroalkyl substances and likelihood of stroke in persons with and without diabetes

2019 ◽  
Vol 17 (1) ◽  
pp. 147916411989222
Author(s):  
Robert Hutcheson ◽  
Kim Innes ◽  
Baqiyyah Conway
Keyword(s):  
Odds Ratio ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Levels ◽  
Perfluorooctanoic Acid ◽  
Cross Sectional Study ◽  
Lipoprotein Cholesterol ◽  
Perfluoroalkyl Substances ◽  
Cross Sectional ◽  
History Of

Objective: The main objective of this study is to evaluate the relationship of perfluoroalkyl substances with stroke and any modifying influence of diabetes. Methods: Data on 3921 adults aged ⩾20 years with and 44,285 without diabetes were drawn from the C8 Health Project. Four perfluoroalkyl substances were investigated: perfluorohexane sulphate, C8 – perfluorooctanoic acid, perfluoroctane sulfonate and perfluorononaoic acid. Results: There were 238 cases of stroke among those with and 643 among those without diabetes. In analyses controlled for age, sex, race, diabetes duration, body mass index, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, C-reactive protein, kidney function and a history of smoking, a history of stroke was significantly inversely associated with serum perfluorohexane sulphate (odds ratio = 0.75, 0.64–0.88) and perfluoroctane sulfonate (odds ratio = 0.81, 0.70–0.90), but not perfluorooctanoic acid (odds ratio = 1.04, 0.94–1.15) or perfluorononaoic acid (odds ratio = 0.89, 0.70–1.14) among those with diabetes. Perfluoroalkyl substances demonstrated no association with stroke among those without diabetes ( p interaction = 0.006 and 0.01 for perfluorohexane sulphate and perfluorooctanoic acid, respectively). Conclusion: In this large cross-sectional study, serum levels of perfluorohexane sulphate and perfluoroctane sulfonate were inversely associated with stroke among those with diabetes. Although mechanisms and implications for this diabetes-specific inverse relationship need to be further explored, our data suggest that perfluoroalkyl substances do not increase risk of stroke among persons with or without diabetes.

Anthracycline exposure and breast cancer risk in female Hodgkin lymphoma survivors.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 12074-12074
Author(s):  
Suzanne I.M. Neppelenbroek ◽  
Yvonne M. Geurts ◽  
Berthe M.P. Aleman ◽  
Cecile P.M. Janus ◽  
Saskia E Rademakers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Hodgkin Lymphoma ◽  
Ductal Carcinoma ◽  
Multivariable Analysis ◽  
Childhood Cancer Survivors ◽  
Potential Contribution ◽  
Increased Risk ◽  
History Of

12074 Background: Female Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Recently concern has been raised that anthracyclines may also increase BC risk, based on studies in childhood cancer survivors with/without a history of chest RT. So far, the association between anthracyclines and BC risk has not been examined in cancer survivors treated at adolescent/adult ages. Now that RT dose and volumes are decreasing, the potential contribution of anthracyclines to BC risk is an important issue. Methods: We assessed BC risk in a cohort of 2314 female 5-year HL survivors, treated at ages 15-50 years and diagnosed between 1965 and 2008 in 20 Dutch hospitals. Treatment factors were time-dependently included in the analysis, focusing on the effect of anthracycline exposure on BC risk. Results: After a median follow-up of 18.8 years, 258 women developed invasive BC or ductal carcinoma in situ as a subsequent malignancy. The 30-year cumulative incidence was 15.0% (95% Confidence Interval (CI) 12.8-17.4%). Mantle field RT (or other RT involving both axillae) was associated with increased risk of BC (Hazard ratio (HR) 1.9; 95% CI 1.2-2.8) compared to no supradiaphragmatic RT or RT to the neck only (Table 1). Gonadotoxic treatment (>4.2 g/m2 procarbazine or pelvic RT) significantly decreased this risk. In a multivariable analysis, anthracycline exposure was associated with increased BC risk (HR 1.8; 95% CI 1.3-2.5) in patients who received a cumulative dose of >200 mg/m2. Among patients exposed to gonadotoxic treatment, the HR of BC associated with >200mg/m2 anthracyclines was 3.8 (95% CI 2.0-7.2), with a trend for higher risk with higher anthracycline dose (HR 1.58 per 100mg/m2 anthracycline, p<0.001). Conclusions: Our results suggest an association of anthracyclines with BC risk in HL survivors. Also when accounting for the protective effect of gonadotoxic treatment on RT-associated BC risk, anthracyclines significantly contributed to a higher BC risk.[Table: see text]

scholarly journals Performance of a household tuberculosis exposure survey among children in a Latin American setting

2019 ◽  
Vol 23 (11) ◽  
pp. 1223-1227 ◽  
Author(s):  
J. Coit ◽  
M. Mendoza ◽  
C. Pinedo ◽  
H. Marin ◽  
S. S. Chiang ◽  
...  
Keyword(s):  
Latin American ◽  
Odds Ratio ◽  
Adjusted Odds Ratio ◽  
Scale Up ◽  
Preventive Therapy ◽  
Mixed Effects ◽  
Skin Tests ◽  
Regression Analyses ◽  
History Of ◽  
Question Survey

OBJECTIVE: To evaluate the performance of a survey that quantifies the intensity of household tuberculosis (TB) exposure among children.METHODS: Children aged 0–14 years in Lima, Peru, with ≥1 signs and/or symptoms of TB and a history of contact with an adult TB patient were included. The 10-question survey was administered to caregivers and addressed sleep proximity, frequency of exposure, and infectiousness of the contact. Infection status was determined using tuberculin skin tests (TSTs). The exposure scale was evaluated for association with TST positivity using mixed-effects regression analyses.RESULTS: The exposure score was significantly associated with TST positivity (age-adjusted odds ratio [aOR] 1.14, 95%CI 1.02–1.28). We observed a stronger association with TST positivity in children aged ≤5 years; (aOR 1.23, 95%CI 1.07–1.41) and no association in children 6–14 years of age (aOR 0.99, 95%CI 0.82–1.20).CONCLUSION: This survey was easy to use and modestly successful in predicting TST positivity in children aged ≤5 years. It may be a useful resource for clinicians for diagnosing TB in children, and for national TB programs aiming to scale up preventive therapy initiatives.

scholarly journals Co-occurrence of thyroid and breast cancer is associated with an increased oncogenic SNP burden

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Bence Bakos ◽  
András Kiss ◽  
Kristóf Árvai ◽  
Balázs Szili ◽  
Barbara Deák-Kocsis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Thyroid Cancer ◽  
Mean Difference ◽  
Genetic Profile ◽  
Retrospective Case ◽  
Monogenic Disorders ◽  
Potential Association ◽  
History Of ◽  
Weighted Number ◽  
The Difference

Abstract Background Epidemiological evidence suggests that synchronous or metachronous presentation of breast and thyroid cancers exceeds that predicted by chance alone. The following potential explanations have been hypothesized: common environmental or hormonal factors, oncogenic effect of the treatment for the first cancer, closer follow-up of cancer survivors, shared underlying genetic risk factors. While some cases were found to be related to monogenic disorders with autosomal inheritance, the genetic background of most cases of co-occurring breast and thyroid cancer is thought to be polygenic. Methods In this retrospective case-control study we compared the genetic profile of patients with a history of breast cancer (n = 15) to patients with co-occurring breast and thyroid cancer (n = 19) using next generation sequencing of 112 hereditary cancer risk genes. Identified variants were categorized based on their known association with breast cancer and oncogenesis in general. Results No difference between patients with breast and double cancers was observed in clinical and pathological characteristics or the number of neutral SNPs. The unweighted and weighted number of SNPs with an established or potential association with breast cancer was significantly lower in the group with breast cancer only (mean difference − 0.58, BCa 95% CI [− 1.09, − 0.06], p = 0.029, and mean difference − 0.36, BCa 95% CI [− 0.70, − 0.02], p = 0.039, respectively). The difference was also significant when we compared the number of SNPs with potential or known association with any malignancy (mean difference − 1.19, BCa 95% CI [− 2.27, − 0.11], p = 0.032 for unweighted, and mean difference − 0.73, BCa 95% CI [− 1.32, − 0.14], p = 0.017 for weighted scores). Conclusion Our findings are compatible with the hypothesis of genetic predisposition in the co-occurrence of breast and thyroid cancer. Further exploration of the underlying genetic mechanisms may help in the identification of patients with an elevated risk for a second cancer at the diagnosis of the first cancer.

Sign in / Sign up

Export Citation Format

Share Document